REG - Arecor Therapeutics - Arecor Partnership with Skye Bioscience

Arecor TherapeuticsAnnouncement

19/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250519:nRSS0919Ja&default-theme=true

RNS Number : 0919J  Arecor Therapeutics PLC  19 May 2025

 

 

Arecor Therapeutics plc

("Arecor" or the "Company")

 

ARECOR ESTABLISHES PARTNERSHIP WITH SKYE BIOSCIENCE TO DEVELOP ENHANCED
FORMULATION OF OBESITY CANDIDATE NIMACIMAB

 

-      Proprietary formulation technology being applied to potentially
enhance properties of nimacimab

 

Cambridge, UK, 19th May 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, today announces a formulation development collaboration with Skye
Bioscience [Nasdaq: SKYE], a clinical-stage biotechnology company focused on
obesity and other metabolic health disorders. The partnership aims to develop
a novel, higher concentration formulation of Skye's CB1 inhibitor, nimacimab,
using Arecor's proprietary formulation technology platform, Arestat™.

 

Skye is evaluating nimacimab, a first-in-class CB1-inhibiting monoclonal
antibody, in its Phase 2a CBeyond™ clinical trial in patients with obesity
and overweight. Data from the initial 26-week treatment period is anticipated
in late Q3 or early Q4 2025.

 

Under the terms of the agreement, Skye Bioscience will fund Arecor's
development activities with the option to license rights to the new
proprietary formulation of nimacimab and associated intellectual property to
further develop and commercialise the product.

 

Sarah Howell, Chief Executive Officer of Arecor, said: "We are pleased to
partner with Skye Bioscience to support the development of a novel, enhanced
formulation of nimacimab, a promising first-in-class candidate with the
potential to address significant unmet needs in metabolic disease. This
collaboration highlights the strength of our proprietary Arestat™ technology
in enabling the development of enhanced therapeutic products that can improve
patient outcomes and supports our strategy of bringing innovative medicines to
market that address significant unmet patient needs in high-value markets. We
have entered 2025 with significant momentum and this marks the third
formulation development collaboration to be established by Arecor with partner
companies so far this year. Together these have a total pre-license deal value
in excess of £1 million, and provide Arecor with significant upside potential
from future licensing opportunities."

 

Tu Diep, Chief Operating Officer of Skye, said: "Approved weight loss drugs
have issues with tolerability and adherence, while the small molecule CB1
inhibitors raise concerns about cumulative exposure-related neuropsychiatric
toxicities. Nimacimab already has an advantageous pharmacokinetic profile and
to date it does not pose these issues. It has a potentially best-in-class
half-life of 18-21 days--substantially longer than GLP-1-based therapies--and
is being evaluated in a Phase 2a study with once-weekly dosing. Serving our
goal of continuous innovation, we are pleased to work with Arecor on the goal
of further enhancing nimacimab to improve patient compliance and treatment
outcomes."

 

-ENDS-

 

For more information, please contact:

 

 Arecor Therapeutics plc                                 www.arecor.com
 Dr Sarah Howell, Chief Executive Officer                Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)
 David Ellam, Chief Financial Officer                    Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)

 Singer Capital Markets Advisory LLP (NOMAD and Broker)
 Phil Davies, Sam Butcher                                Tel: +44 (0) 20 7496 3000

 ICR Healthcare
 Chris Gardner, David Daley, Lindsey Neville             Tel: +44 (0) 20 3709 5700

                                                         Email: arecor@icrhealthcare.com (mailto:arecor@icrhealthcare.com)

 

SKYE CONTACTS

Investor Relations

ir@skyebioscience.com

(858) 410-0266

 

LifeSci Advisors, Mike Moyer

mmoyer@lifesciadvisors.com

(617) 308-4306

 

Media Inquiries

LifeSci Communications, Michael Fitzhugh

mfitzhugh@lifescicomms.com

(628) 234-3889

 

 

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.  For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

About Skye Bioscience

Skye is focused on unlocking new therapeutic pathways for metabolic health
through the development of next-generation molecules that modulate G-protein
coupled receptors. Skye's strategy leverages biologic targets with substantial
human proof of mechanism for the development of first-in-class therapeutics
with clinical and commercial differentiation. Skye is conducting a Phase 2a
clinical trial (ClinicalTrials.gov: NCT06577090
(https://www.globenewswire.com/Tracker?data=9H5BOu1XUbgfnaBhP1p_htCUkUd81oUzPG1DW3KoCb7G8IEGTRJdvvsNCdkM-yghs2Ptn9bOSlz7dXfQC14W3vrm6964r-C7vC7HWAxddscrx8siB0V0Ti7FUTpAMaHAfj4_ZBE2iuLj3zM49J5Arw==)
) in obesity for nimacimab, a negative allosteric modulating antibody that
peripherally inhibits CB1. This study is also assessing the combination of
nimacimab and a GLP-1R agonist (Wegovy®). For more information, please
visit: www.skyebioscience.com
(https://www.globenewswire.com/Tracker?data=YXhcZLOU0fhTgcZbQy3Vr-nBNLqZuzg-BzU8e8fI8hmHFKd4pD_SZpxpY1R50t45CEX98KTrFLcyxRnImNEVaYrNHeyjSXqP3YUQk7w_aco=)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGREAKSKFAASEFA